MPGES-1 as a target for cancer suppression. A comprehensive invited review "Phospholipase A2 and lipid mediators"

Biochimie

Volumn 92, Issue 6, 2010, Pages 660-664

  Nakanishi, Masako ^a   Gokhale, Vijay ^b   Meuillet, Emmanuelle J ^b   Rosenberg, Daniel W ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cancer; Inflammation; MPGES 1; MPGES 1 inhibitor; PGE2

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENZYME INHIBITOR; IRGASAN; LIPID; MF 63; MK 866; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PIRINIXIC ACID; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E SYNTHASE 1 INHIBITOR; PROSTAGLANDIN E2; ROFECOXIB; TRICLOSAN; UNCLASSIFIED DRUG;

ADENOMA; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL SURFACE; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INFLAMMATION; NONHUMAN; PROTEIN FAMILY; PROTEIN LOCALIZATION; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; NEOPLASMS; PHOSPHOLIPASES A2;

EID: 77953290938     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.02.006     Document Type: Short Survey

References (62)

1. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
2. Smith W.L. The eicosanoids and their biochemical mechanisms of action. Biochem. J. 1989, 259:315-324.
3. Wang D., Buchanan F.G., Wang H., Dey S.K., DuBois R.N. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 2005, 65:1822-1829.
4. Kobayashi T., Narumiya S. Prostanoids in health and disease; lessons from receptor-knockout mice. Adv. Exp. Med. Biol. 2002, 507:593-597.
5. Breyer R.M., Bagdassarian C.K., Myers S.A., Breyer M.D. Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 2001, 41:661-690.
6. Samuelsson B., Morgenstern R., Jakobsson P.J. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev. 2007, 59:207-224.
7. Pugh S., Thomas G.A. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994, 35:675-678.
8. Baron J.A., Cole B.F., Sandler R.S., et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl. J. Med. 2003, 348:891-899.
9. Sandler R.S., Halabi S., Baron J.A., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 2003, 348:883-890.
10. Smalley W.E., DuBois R.N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 1997, 39:1-20.
11. Thun M.J., Namboodiri M.M., Heath C.W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 1991, 325:1593-1596.
12. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005, 352:1092-1102.
13. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 2005, 352:1081-1091.
14. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005, 352:1071-1080.
15. Jakobsson P.J., Thoren S., Morgenstern R., Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:7220-7225.
16. Murakami M., Naraba H., Tanioka T., et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem. 2000, 275:32783-32792.
17. Wang M., Song W.L., Cheng Y., Fitzgerald G.A. Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease. J. Intern. Med. 2008, 263:500-505.
18. Kobayashi T., Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat. 2002, 68-69:557-573.
19. Ushikubi F., Sugimoto Y., Ichikawa A., Narumiya S. Roles of prostanoids revealed from studies using mice lacking specific prostanoid receptors. Jpn. J. Pharmacol. 2000, 83:279-285.
20. Kamei D., Murakami M., Nakatani Y., Ishikawa Y., Ishii T., Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J. Biol. Chem. 2003, 278:19396-19405.
21. Yoshimatsu K., Golijanin D., Paty P.B., et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin. Cancer Res. 2001, 7:3971-3976.
22. Yoshimatsu K., Altorki N.K., Golijanin D., et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin. Cancer Res. 2001, 7:2669-2674.
23. Gudis K., Tatsuguchi A., Wada K., et al. Clinical significance of prostaglandin E synthase expression in gastric cancer tissue. Hum. Pathol. 2007, 38:1826-1835.
24. Hasan S., Satake M., Dawson D.W., et al. Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas 2008, 37:121-127.
25. Herfs M., Herman L., Hubert P., et al. High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunol. Immunother. 2009, 58:603-614.
26. Hanaka H., Pawelzik S.C., Johnsen J.I., et al. Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:18757-18762.
27. Omi Y., Shibata N., Okamoto T., Obara T., Kobayashi M. Immunohistochemical demonstration of membrane-bound prostaglandin E(2) synthase-1 in papillary thyroid carcinoma. Acta Histochem. Cytochem. 2009, 42:105-109.
28. Camacho M., Leon X., Fernandez-Figueras M.T., Quer M., Vila L. Prostaglandin E(2) pathway in head and neck squamous cell carcinoma. Head Neck 2008, 30:1175-1181.
29. Baryawno N., Sveinbjornsson B., Eksborg S., et al. Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro Oncol. 2008, 10:661-674.
30. Mattila S., Tuominen H., Koivukangas J., Stenback F. The terminal prostaglandin synthases mPGES-1, mPGES-2, and cPGES are all overexpressed in human gliomas. Neuropathology 2009, 29:156-165.
31. Seo T., Tatsuguchi A., Shinji S., et al. Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients. Virchows Arch. 2009, 454:667-676.
32. Kamei D., Murakami M., Sasaki Y., et al. Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. Biochem. J. 2009.
33. Lazarus M., Kubata B.K., Eguchi N., Fujitani Y., Urade Y., Hayaishi O. Biochemical characterization of mouse microsomal prostaglandin E synthase-1 and its colocalization with cyclooxygenase-2 in peritoneal macrophages. Arch. Biochem. Biophys. 2002, 397:336-341.
34. Stark K., Bylund J., Torma H., Sahlen G., Oliw E.H. On the mechanism of biosynthesis of 19-hydroxyprostaglandins of human seminal fluid and expression of cyclooxygenase-2, PGH 19-hydroxylase (CYP4F8) and microsomal PGE synthase-1 in seminal vesicles and vas deferens. Prostaglandins Other Lipid Mediat. 2005, 75:47-64.
35. Kulmacz R.J., Wang L.H. Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. J. Biol. Chem. 1995, 270:24019-24023.
36. Matsumoto H., Naraba H., Murakami M., et al. Concordant induction of prostaglandin E2 synthase with cyclooxygenase-2 leads to preferred production of prostaglandin E2 over thromboxane and prostaglandin D2 in lipopolysaccharide-stimulated rat peritoneal macrophages. Biochem. Biophys. Res. Commun. 1997, 230:110-114.
37. Thoren S., Jakobsson P.J. Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4. Eur. J. Biochem. 2000, 267:6428-6434.
38. Stichtenoth D.O., Thoren S., Bian H., Peters-Golden M., Jakobsson P.J., Crofford L.J. Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J. Immunol. 2001, 167:469-474.
39. Uematsu S., Matsumoto M., Takeda K., Akira S. Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J. Immunol. 2002, 168:5811-5816.
40. Nakanishi M., Montrose D.C., Clark P., et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res. 2008, 68:3251-3259.
41. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310:1504-1510.
42. Elander N., Ungerback J., Olsson H., Uematsu S., Akira S., Soderkvist P. Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice. Biochem. Biophys. Res. Commun. 2008, 372:249-253.
43. Maggio-Price L., Treuting P., Zeng W., Tsang M., Bielefeldt-Ohmann H., Iritani B.M. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res. 2006, 66:828-838.
44. Oshima H., Oshima M., Inaba K., Taketo M.M. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 2004, 23:1669-1678.
45. Nardone G., Rocco A., Vaira D., et al. Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H. pylori-related gastric carcinogenesis. J. Pathol. 2004, 202:305-312.
46. Baron J.A., Sandler R.S., Bresalier R.S., et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008, 372:1756-1764.
47. Clemett D., Goa K.L. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000, 59:957-980.
48. Matheson A.J., Figgitt D.P. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs 2001, 61:833-865.
49. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit. Rev. Clin. Lab. Sci. 2000, 37:431-502.
50. Futaki N., Yoshikawa K., Hamasaka Y., et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen. Pharmacol. 1993, 24:105-110.
51. Degousee N., Fazel S., Angoulvant D., et al. Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 2008, 117:1701-1710.
52. Wang M., Zukas A.M., Hui Y., Ricciotti E., Pure E., FitzGerald G.A. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:14507-14512.
53. Wu D., Mennerich D., Arndt K., et al. Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 inhibition in acute cardiac ischemia in mice. Prostaglandins Other Lipid Mediat. 2009, 90:21-25.
54. Cheng Y., Wang M., Yu Y., Lawson J., Funk C.D., Fitzgerald G.A. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest. 2006, 116:1391-1399.
55. Arai I., Hamasaka Y., Futaki N., et al. Effect of NS-398, a new nonsteroidal anti-inflammatory agent, on gastric ulceration and acid secretion in rats. Res. Commun. Chem. Pathol. Pharmacol. 1993, 81:259-270.
56. Quraishi O., Mancini J.A., Riendeau D. Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-Delta(12,14)-prostaglandin J(2) and polyunsaturated fatty acids. Biochem. Pharmacol. 2002, 63:1183-1189.
57. Riendeau D., Aspiotis R., Ethier D., et al. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg. Med. Chem. Lett. 2005, 15:3352-3355.
58. Koeberle A., Zettl H., Greiner C., Wurglics M., Schubert-Zsilavecz M., Werz O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J. Med. Chem. 2008, 51:8068-8076.
59. Xu D., Rowland S.E., Clark P., et al. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J. Pharmacol. Exp. Ther. 2008, 326:754-763.
60. Wallace J.L. Selective COX-2 inhibitors: is the water becoming muddy?. Trends Pharmacol. Sci. 1999, 20:4-6.
61. San Juan A.A., Cho S.J. 3D-QSAR study of microsomal prostaglandin E2 synthase (mPGES-1) inhibitors. J. Mol. Model. 2007, 13:601-610.
62. DuBois R.N., Giardiello F.M., Smalley W.E. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol. Clin. North Am. 1996, 25:773-791.